If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Strattera ® (atomoxetine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Strattera Summary of Product Characteristics (SmPC)
Strattera® (atomoxetine): Fertility, pregnancy and lactation
Atomoxetine should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus
Pregnancy
Animal studies in general do
not indicate direct harmful effects with respect to pregnancy,
embryonal/foetal development, parturition or postnatal development.
For atomoxetine clinical data on exposed pregnancies are limited.
Such data are insufficient to indicate either an association or a
lack of association between atomoxetine and adverse pregnancy and/or
lactation outcomes. Atomoxetine should not be used during pregnancy
unless the potential benefit justifies the potential risk to the
foetus.
Breast-feeding
Atomoxetine and/or its
metabolites were excreted in the milk of rats. It is not known if
atomoxetine is excreted in human milk. Because of the lack of data,
atomoxetine should be avoided during breast-feeding.
REFERENCE
Strattera
Summary of Product Characteristics
Date of Last Review:November 02, 2018
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com